|  | Collecting Quality Data in Psychiatric Trials Understanding interactions among the many factors that give rise to mental illness is a complex task. Learn how to identify and mitigate these elements early on to help ensure trial data accurately captures your compound’s safety and efficacy potential. Premier Research. Built for BiotechSM |
Today's Rundown Featured Story | | | Monday, March 23, 2020 Eli Lilly is slashing its clinical trial activities in response to the COVID-19 pandemic. With the novel coronavirus putting healthcare systems under tremendous strain, Lilly has decided to delay most trial starts and pause enrollment in most ongoing studies. |
|
|---|
|
|  | Metabolon reveals a new ally for drug research and development programs. Learn more. |
Top Stories 2019 will likely go down as a landmark year for biopharma partnering, at least when looking at the sums involved. Monday, March 23, 2020 Life science venture capital firm Syncona is warning of serious delays to studies across its biotech portfolio. Monday, March 23, 2020 Since the early days of the current coronavirus outbreak, Gilead Sciences’ experimental antiviral drug remdesivir has been hailed as a leading hope. That halo has apparently overwhelmed the Big Biotech, which has temporarily stopped granting patients emergency access to remdesivir due to an “exponential increase” in requests. Monday, March 23, 2020 There is no treatment for inherited degenerative disorders like Friedreich's ataxia, so care focuses on relieving symptoms. With $45 million and technology out of the University of Wisconsin, Design Therapeutics is trying to change that. The funding will push its lead program into the clinic. Monday, March 23, 2020 AlloVir and Baylor College of Medicine have teamed up to develop T-cell therapies against the novel coronavirus behind the COVID-19 pandemic outbreak. The alliance builds on existing work to create off-the-shelf cell therapies that identify and eliminate specific viruses. Monday, March 23, 2020 German pharma Boehringer Ingelheim has decided it will no longer work on Zealand Pharma’s experimental diabetes therapy, leaving the biotech to think about next steps for the program. Saturday, March 21, 2020 The FDA has authorized its first rapid, point-of-care diagnostic for the novel coronavirus—allowing physicians in hospitals, clinics and emergency rooms to test a sample for the disease in about 45 minutes. Friday, March 20, 2020 After two weeks of sleepless nights, growing comfort with conference calls and "esprit de corps," Regeneron researchers are making headway toward a COVID-19 therapy with the backing of international regulators and a "shared sense of urgency," said David Weinreich, Regeneron's head of global clinical development, on Friday. Monday, March 23, 2020 The bracket is set for #FierceMadness. With play-in winners determined, FiercePharma's drug naming tournament moves into its full 64 name match-ups across four condition-grouped divisions. Enrollment Showcase | | | Presented by: Global EMBA for Healthcare & the Life Sciences, University of Toronto Prepare to step up in your career, build the expertise you need to reshape your organization, and explore opportunities worldwide. |
|
|---|
|
Resources Sponsored by: Patheon, by Thermo Fisher Scientific Poorly soluble molecules hindering your workflow? Sponsored by: eClinical Solutions Key findings from the 2019 Life Sciences Data & Analytics Survey conducted by the Tufts Center for the Study of Drug Development will be unveiled during this live webinar led by industry expert and study lead, Ken Getz, Director of Sponsored Programs and Associate Professor. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Outer Edge Technology See why innovative BioPharma’s are partnering with Cloud Service Provider’s to design, manage and implement cloud strategies to smooth the path to FDA approval and enhance their competitive prowess. Sponsored by: Metabolon Metabolomics can help you streamline your drug development process by providing the framework to make a stronger, more confident, and more valuable case for a molecule in a shorter timeframe. Sponsored by: Epsilon Download this e-book to learn 9 ways to enhance the customer experience within healthcare marketing. Sponsored by: Reprints Desk/Research Solutions 3 ways you may be overspending on scientific literature access, and how to fix them. Sponsored by: Baxter When different drug products are produced in shared facilities, potential for cross-contamination needs to be addressed. Outsourcing to a CMO with experience in multiproduct facilities can be an option. Sponsored by: WCG Metrics Champion Consortium Ineffective measurement could mean wasting both time and money. This whitepaper showcases a custom-built Metric Maturity Model that helps illustrate and define the process for measuring the right things the right way. Sponsored by: The Kinetix Group Read about the innovative ways payers are making smart moves in the healthcare game. Sponsored by: Catalent This whitepaper discusses the benefits of end-to-end solutions and share case studies on how flexible manufacturing strategies can accommodate the changing landscape of pharmaceutical products and help bring a drug to market. Sponsored by: Catalent Get expert insights on strategies to implement flexible manufacturing and different technologies that are easily scalable and reproducible. Sponsored by: Catalent Regardless of the assigned FDA expedited approval designation and approach, the key action items should be: the assurance of a detail-oriented plan and the adaption of a “forward-thinking” approach that will assist in any future challenges and opportunities for growth of each project. | 
